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Imagine having to wait almost 2 months to begin treatment for a highly fatal disease likelung cancer. Most clinicians would find this unacceptable, but studies in diverse health
care settings across different countries indicate that this is the rule and not the exception.1
Admittedly, caring for the patient with lung cancer requires a complicated sequence of
coordinated steps, and, given a choice, it is probably more important to be correct in
diagnosis, staging, and treatment planning than it is to be timely. In fact, an association
between timely lung cancer care and improved survival has not been demonstrated.
Accordingly, some might argue that delays in care are of little consequence and that the
additional emotional distress experienced by already stressed patients and family members
is something that can and should be addressed by managing their expectations.
This argument might be persuasive to some, but it rests on the assumption that most
or all delays in care are inevitable, when some of the known causes of delay can in fact
be avoided, including initial referrals to nonrespiratory physicians and transfers between
hospitals.1 In addition, the Institute of Medicine defines high-quality health care as being
not only safe and effective but also timely, patient centered, and equitable.2 Finally, just
because an association between timeliness and survival has not been demonstrated does
not mean that one does not exist. The effect of timely care on survival obviously does not
lend itself to a randomized, controlled trial, and previous observational studies have been
limited by selection bias and residual confounding.
In this issue of Journal of Thoracic Oncology, Yorio et al.3 report the results of a
retrospective cohort study that examined timeliness of care in 482 patients with stage I–III
non-small cell lung cancer at hospitals affiliated with the University of Texas Southwest-
ern Medical Center. Of note, most previous studies of timeliness were conducted in
European Union member countries and Japan, and all but two previous studies of
timeliness in the United States were conducted in Department of Veterans Affairs (VA)
settings, limiting their potential generalizability to other U.S. health care settings where
the majority of Americans with lung cancer receive their care.4,5
The authors found that the interval between the first abnormal imaging test and
treatment was approximately 40% longer in patients who were evaluated and managed at
the public hospital in their system (median 76 days) compared with those who received
care at one of the two private hospitals (median 45 days). Even more strikingly, the image
to treatment interval was longer than 116 days in 25% of those treated at the public
hospital, and it was longer than 78 days in 25% of those treated at the private hospitals.
In a Cox proportional hazards analysis that adjusted for age, sex, race, and insurance
coverage, time to treatment was associated only with hospital type. The instantaneous
“risk” of receiving treatment at any time was 85% greater in patients who received care
at one of the private hospitals. Perhaps not surprisingly, patients treated at the public
hospital were younger, more likely to be black or Hispanic, less likely to have private
insurance, and more likely to live in a neighborhood characterized by lower socioeco-
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nomic status and lower rates of high school graduation.
Distressingly, patients treated at the public hospital were
almost 40% more likely to present with more advanced (stage
III) disease. With regard to timeliness, the care delivered at
the public and private hospitals was clearly not equitable in
this study. Other studies in lung cancer have found racial and
ethnic disparities in staging practices, treatments and out-
comes, but the underlying causes are not completely under-
stood.6–8 The study by Yorio et al. lends support to the
hypothesis that variable access to (timely) care may be one of
the mechanisms responsible for racial and ethnic disparities.
Similar to most previous studies, the authors found that
timeliness was not associated with stage distribution or sur-
vival,9,10 but the possibility of residual confounding warrants
additional emphasis. Patients with more symptomatic disease
are, on average, probably more likely to receive timely care
than those with fewer or less severe symptoms. If the biologic
aggressiveness of disease is correlated with symptoms, as
seems likely, then this could easily obscure a (negative)
association between timeliness and survival. For instance, a
patient who presents with symptoms and signs of spinal cord
compression is not only more likely to receive prompt diag-
nosis and treatment than a patient with an incidentally de-
tected malignant pulmonary nodule but also more likely to
die soon. Future studies on timeliness and survival should
make use of more sophisticated methods for analyzing non-
experimental data, such as propensity scores and instrumental
variables.
Although the study by Yorio et al. was otherwise meth-
odologically strong and elegantly presented, limitations in-
clude the relatively small sample, possible referral center
bias, uncertain generalizability to other health care settings
and regions of the country, and the exclusion of patients with
stage IV non-small cell lung cancer, which, at least in theory,
could result in systematically excluding patients who had
long delays that resulted in progression to advanced disease.
Hence, future studies of timeliness should examine large,
population-based samples and include patients across the full
spectrum of disease stage.
Other important questions remain unanswered. Timeli-
ness of care was vastly different at the public and private
hospitals, despite the fact that the same physicians cared for
patients in both settings. What were the specific barriers to
providing more timely care at the public hospital and what
can be done to overcome these barriers? A qualitative study
of timely care in lung cancer in VA settings identified multiple
barriers, including inadequate staffing, limited availability of
imaging equipment and operating room time, suboptimal
coordination of care within and between facilities, institu-
tional inertia, and patient noncompliance.11 To what extent
these or other factors operate in non-VA settings is an
important question for future studies. More importantly, rig-
orously designed interventions to improve timeliness should
target settings where the opportunities for improvement are
greatest and the need is most urgent. All persons should have
access to high-quality, timely health care, especially when
facing a deadly killer like lung cancer.
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